The trial showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival.
More Stories
Intel’s stock seals strong week. But would a Qualcomm merger make sense?
One fund manager sees “more cons than pros” if the companies were to combine, after the Wall Street Journal reported...
Boeing’s defense chief is leaving, company says
Boeing Co. said that Ted Colbert — its head of defense, space and security — would leave the company on...
The Fed decision’s lone dissenter worries the bigger rate cut sends a ‘premature victory’ message to markets
Michelle Bowman was the first Federal Reserve governor to dissent from an interest-rate decision since 2005.
Tech giants desperate to power AI data centers are turning to nuclear disaster sites — despite the risks
The tech industry’s need for more power for data centers running artificial intelligence is now so desperate that companies are...
Jamie Dimon: Only 5% of everyday Americans probably know about the Fed’s historic interest-rate cut
JPMorgan Chase CEO Jamie Dimon suggests the half-point interest-rate cut is “a minor thing” that Wall Street — not Main...
Uranium ETFs rally amid plans to revive nuclear reactor in Microsoft agreement
Constellation Energy said Friday it plans to restart a nuclear reactor at Three Mile Island.